The potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin. Cancer Res., 8: 1172-1181, 2002

Clin Cancer Res. 2002 Apr;8(4):955-6.

Authors

Doris R Siwak¹, Ana M Tari, Gabriel Lopez-Berestein

Affiliation

¹ Department of Bioimmunotherapy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

PMID: 11948099

No abstract available

Publication types

Comment

MeSH terms

Animals
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / immunology*
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / therapeutic use*
Breast Neoplasms / drug therapy
Breast Neoplasms / pathology
Doxorubicin / administration & dosage
Doxorubicin / therapeutic use*
Drug Delivery Systems / methods
Drug Synergism
Humans
Immunoglobulin Fragments / administration & dosage
Immunoglobulin Fragments / immunology
Liposomes
Mammary Neoplasms, Experimental / drug therapy
Mammary Neoplasms, Experimental / pathology
Mice
Mice, Nude
Rats
Receptor, ErbB-2 / immunology*
Treatment Outcome
Xenograft Model Antitumor Assays

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Immunoglobulin Fragments
Liposomes
Doxorubicin
Receptor, ErbB-2